Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INSM NASDAQ:KRYS NASDAQ:ONC NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSMInsmed$106.24$137.89$65.56▼$212.75$23.03B0.894.03 million shs2.43 million shsKRYSKrystal Biotech$299.45$272.14$122.80▼$319.48$8.83B0.5316,855 shs162,215 shsONCBeOne Medicines$310.25$300.77$235.35▼$385.22$34.04B0.5230,234 shs190,918 shsRVMDRevolution Medicines$151.56$123.75$34.00▼$156.25$32.22B1.412.69 million shs1.93 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSMInsmed0.00%-2.66%-21.40%-33.19%+57.32%KRYSKrystal Biotech0.00%-2.23%+9.88%+9.05%+139.46%ONCBeOne Medicines0.00%+5.79%+3.14%-16.29%+28.51%RVMDRevolution Medicines0.00%+4.05%+12.02%+46.17%+281.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSMInsmed$106.24$137.89$65.56▼$212.75$23.03B0.894.03 million shs2.43 million shsKRYSKrystal Biotech$299.45$272.14$122.80▼$319.48$8.83B0.5316,855 shs162,215 shsONCBeOne Medicines$310.25$300.77$235.35▼$385.22$34.04B0.5230,234 shs190,918 shsRVMDRevolution Medicines$151.56$123.75$34.00▼$156.25$32.22B1.412.69 million shs1.93 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSMInsmed0.00%-2.66%-21.40%-33.19%+57.32%KRYSKrystal Biotech0.00%-2.23%+9.88%+9.05%+139.46%ONCBeOne Medicines0.00%+5.79%+3.14%-16.29%+28.51%RVMDRevolution Medicines0.00%+4.05%+12.02%+46.17%+281.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSMInsmed 2.96Moderate Buy$210.9598.56% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.118.24% UpsideONCBeOne Medicines 2.80Moderate Buy$389.1525.43% UpsideRVMDRevolution Medicines 3.00Buy$111.35-26.53% DownsideCurrent Analyst Ratings BreakdownLatest KRYS, ONC, RVMD, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$151.005/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026RVMDRevolution Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.005/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/15/2026ONCBeOne Medicines Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$364.00 ➝ $367.005/13/2026INSMInsmed Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$205.00 ➝ $185.005/8/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$230.00 ➝ $226.005/8/2026INSMInsmed Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$220.00 ➝ $205.005/8/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$177.00 ➝ $160.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSMInsmed$819.56M28.10N/AN/A$3.25 per share32.69KRYSKrystal Biotech$389.13M22.69$7.29 per share41.08$43.31 per share6.91ONCBeOne Medicines$5.34B6.37$3.91 per share79.38$43.39 per share7.15RVMDRevolution Medicines$11.58M2,782.53N/AN/A$7.06 per share21.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSMInsmed-$1.28B-$5.75N/A123.53N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.0328.46N/A53.92%19.25%17.62%8/3/2026 (Estimated)ONCBeOne Medicines$286.93M$4.4769.4129.92N/A8.94%12.06%6.69%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)Latest KRYS, ONC, RVMD, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billion2/26/2026Q4 2025ONCBeOne Medicines$1.60$0.58-$1.02$0.58$1.45 billion$1.50 billion2/25/2026Q4 2025RVMDRevolution Medicines-$1.56-$1.86-$0.30-$1.86$3.89 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINSMInsmedN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSMInsmed0.804.474.10KRYSKrystal BiotechN/A9.469.06ONCBeOne Medicines0.203.643.27RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSMInsmedN/AKRYSKrystal Biotech86.29%ONCBeOne Medicines48.55%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipINSMInsmed2.10%KRYSKrystal Biotech13.10%ONCBeOne Medicines6.19%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSMInsmed1,664216.75 million212.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ARVMDRevolution Medicines250212.60 million195.16 millionOptionableKRYS, ONC, RVMD, and INSM HeadlinesRecent News About These CompaniesJefferies Financial Group Inc. Acquires 1,128,195 Shares of Revolution Medicines, Inc. $RVMDMay 24 at 5:51 AM | marketbeat.comCatalyst Funds Management Pty Ltd Purchases 13,400 Shares of Revolution Medicines, Inc. $RVMDMay 24 at 4:08 AM | marketbeat.comBernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendationMay 23 at 7:21 AM | msn.comRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO PresentationMay 21, 2026 | globenewswire.comEagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMDMay 21, 2026 | marketbeat.comProfund Advisors LLC Has $2.15 Million Stock Holdings in Revolution Medicines, Inc. $RVMDMay 20, 2026 | marketbeat.comNeedham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider LossMay 20, 2026 | insidermonkey.comGraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum StocksMay 19, 2026 | benzinga.comAssessing Revolution Medicines (RVMD) Valuation After A Powerful Multi Year Shareholder Return RunMay 17, 2026 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from AnalystsMay 17, 2026 | americanbankingnews.comCancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: ReportMay 15, 2026 | benzinga.comAIHC Capital Management Ltd Acquires New Holdings in Revolution Medicines, Inc. $RVMDMay 15, 2026 | marketbeat.comRevolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside PotentialMay 14, 2026 | tipranks.comUS cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drugMay 14, 2026 | reuters.comQ2 EPS Forecast for Revolution Medicines Lowered by AnalystMay 11, 2026 | marketbeat.comRevolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for DaraxonrasibMay 10, 2026 | insidermonkey.comIs It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge?May 10, 2026 | finance.yahoo.comRevolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 ExpiryMay 8, 2026 | tipranks.comRevolution Medicines Signals Breakout With RAS WinsMay 7, 2026 | tipranks.comRoyal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00May 7, 2026 | marketbeat.comRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBerkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026Spotify’s Ad Slump Raises a Bigger Question Than You ThinkBy Chris Markoch | April 29, 20263 Emerging Markets ETFs to Maximize Exposure to High-Potential CountriesBy Nathan Reiff | May 4, 2026Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and BookingBy Jessica Mitacek | May 7, 2026KRYS, ONC, RVMD, and INSM Company DescriptionsInsmed NASDAQ:INSM$106.24 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$106.50 +0.26 (+0.24%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Krystal Biotech NASDAQ:KRYS$299.45 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$304.00 +4.55 (+1.52%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.BeOne Medicines NASDAQ:ONC$310.25 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$305.65 -4.60 (-1.48%) As of 05/22/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Revolution Medicines NASDAQ:RVMD$151.56 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$151.50 -0.06 (-0.04%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
